Immunome (NASDAQ:IMNM) Earns Overweight Rating from Stephens

Immunome (NASDAQ:IMNM - Get Free Report)'s stock had its "overweight" rating reiterated by research analysts at Stephens in a research report issued on Thursday,Benzinga reports. They currently have a $30.00 price objective on the stock. Stephens' target price suggests a potential upside of 268.10% from the stock's current price.

A number of other research firms have also issued reports on IMNM. Wedbush reaffirmed an "outperform" rating and issued a $33.00 target price on shares of Immunome in a report on Monday, March 10th. Lifesci Capital assumed coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective on the stock. Finally, Guggenheim cut their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $25.50.

Immunome Stock Performance

Shares of Immunome stock traded down $0.03 on Thursday, reaching $8.15. The stock had a trading volume of 960,264 shares, compared to its average volume of 827,037. Immunome has a fifty-two week low of $8.12 and a fifty-two week high of $26.70. The business's 50-day moving average price is $9.72 and its two-hundred day moving average price is $11.49. The stock has a market cap of $650.18 million, a P/E ratio of -1.00 and a beta of 1.93.

Remove Ads

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, equities analysts forecast that Immunome will post -2.21 earnings per share for the current fiscal year.

Insider Activity

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the firm's stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares of the company's stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immunome

A number of hedge funds have recently made changes to their positions in IMNM. BNP Paribas Financial Markets bought a new stake in Immunome in the fourth quarter valued at about $70,000. KLP Kapitalforvaltning AS acquired a new stake in Immunome during the fourth quarter valued at approximately $75,000. AlphaQuest LLC boosted its holdings in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new position in shares of Immunome in the 4th quarter worth approximately $95,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.